SRU Biosystems granted US patent for optical biosensors

The patent includes claims for optical biosensors and their use in a wide variety of assay formats, including the detection of substances in unpurified biological samples. The patent adds to the expansive coverage that the company has secured for its core technologies, including its instrumentation, microplate designs, and product applications.

The patent is related to the SRU BIND technology, which includes instrumentation such as the Cartridge Reader (for 8- and 16-well biosensors), BIND 96/384 Reader TURBO, capable of 96- and 384-well microplate detection, and the recently introduced BIND 384/1536 Reader TURBO, with its first-in-class 1536-well label-free detection capacity.

According to the comapany, the SRU BIND Reader can be easily integrated into automated systems and represents one of the most cost-effective solutions for high throughput label-free detection on the market for antibody and small molecule/fragment screening, and cell-based applications.

Richard Wagner, president and CEO of SRU Biosystems, said: “This patent broadly covers our technology and its use with unpurified biological samples to detect a wide array of binding events, such as antibody-antigen or protein-small molecule interactions.”